Skip to main content

Uveitis clinical trials at University of California Health

3 research studies open to eligible people

Showing trials for
  • Adalimumab in JIA-associated Uveitis Stopping Trial

    open to eligible people ages 2 years and up

    The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or ANA-positive cronic anterior uveitis (CAU).

    at UC Davis UCSF

  • Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

    open to eligible people ages 13 years and up

    Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.

    at UCLA UCSF

  • Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

    open to eligible people ages 18 years and up

    This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be randomized to receive MDS testing results or not to receive MDS testing results. All patients will receive standard-of-care testing to guide management. Enrolled patients will be followed at week 2, week 3-6 (randomization visit), and at 4 weeks after the randomization visit. The proportions of patients who received the appropriate therapy and the proportions of patients with improved outcome will be compared between arms. Patient quality of life, MDS performance, and the provider certainly of belief will be collected.

    at UC Davis UCLA UCSF

Our lead scientists for Uveitis medical studies include .

Last updated: